1. Home
  2. DAVA vs BDSX Comparison

DAVA vs BDSX Comparison

Compare DAVA & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$3.00

Market Cap

159.1M

Sector

Technology

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

N/A

Current Price

$27.40

Market Cap

276.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DAVA
BDSX
Founded
2000
2005
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Precision Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.1M
276.2M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
DAVA
BDSX
Price
$3.00
$27.40
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$13.50
$32.50
AVG Volume (30 Days)
198.9K
116.4K
Earning Date
05-19-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
N/A
$25.26
Revenue Next Year
$4.07
$19.15
P/E Ratio
$20.02
N/A
Revenue Growth
N/A
24.08
52 Week Low
$2.55
$5.26
52 Week High
$9.97
$31.31

Technical Indicators

Market Signals
Indicator
DAVA
BDSX
Relative Strength Index (RSI) 49.59 53.35
Support Level $2.64 $24.07
Resistance Level $3.03 $31.31
Average True Range (ATR) 0.13 2.04
MACD -0.03 -0.22
Stochastic Oscillator 41.27 32.18

Price Performance

Historical Comparison
DAVA
BDSX

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Share on Social Networks: